State Street’s Indivior Pharmaceuticals INDV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$205M Buy
4,992,071
+88,078
+2% +$3.2M 0.01% 1038
2026
Q1
$149M Buy
4,903,993
+244,712
+5% +$8.08M 0.01% 1128
2025
Q4
$167M Buy
4,659,281
+1,844,532
+66% +$56.3M 0.01% 1050
2025
Q3
$67.9M Buy
2,814,749
+1,244,408
+79% +$26M ﹤0.01% 1573
2025
Q2
$23.1M Buy
+1,570,341
New +$18.3M ﹤0.01% 2112

Other funds holding INDV

State Street's INDV Position: Q2 2026 in Review

State Street increased its Indivior Pharmaceuticals (INDV) stake by 1.8% in Q2 2026, buying an estimated $3.2M and bringing the position to 4,992,071 shares worth $205M. The position accounts for 0.01% of the portfolio, ranked #1038.

State Street first reported a position in INDV in Q2 2025 and has held it in 5 quarters since. 336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • State Street held 4,992,071 shares of Indivior Pharmaceuticals worth $205M as of Q2 2026.
  • State Street bought 88,078 Indivior Pharmaceuticals shares in Q2 2026, an estimated $3.2M.
  • Indivior Pharmaceuticals made up 0.01% of State Street's portfolio in Q2 2026, its #1038 holding.
  • State Street first reported a position in Indivior Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.